long life Thanks to Kitaruda
FDA Expands Keytruda® Approval for Front Line Treatment of NSCLC
On April 14, 2019, the FDA approved Keytruda® as first line monotherapy for non-small cell lung, NSCLC, cancer patients whose cancer cells express PD-L1 and have no genomic changes in…